Text Size

Epoetin Beta in Treating Anemia in Patients With Cervical Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00046969
First received: October 3, 2002
Last updated: May 9, 2009
Last verified: March 2007
History of Changes
  Purpose

RATIONALE: Epoetin beta may stimulate red blood cell production to prevent or control anemia in patients treated with chemotherapy and radiation therapy.

PURPOSE: Randomized phase IV trial to determine the effectiveness of epoetin beta in treating anemia in patients who are receiving cisplatin and radiation therapy for stage IIB, stage III, or stage IVA cervical cancer.


Condition Intervention Phase
Anemia
Cervical Cancer
 Biological: epoetin beta
Drug: cisplatin
Radiation: brachytherapy
Radiation: radiation therapy
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Radiotherapy Plus Cisplatin)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Number of treatment failures within 6 months after beginning radiochemotherapy (RCT) (stage I)
  • Overall survival after RCT (stage II)

Secondary Outcome Measures:
  • Progression/relapse-free survival
  • Overall response rate to RCT
  • Overall survival after RCT (stage I)
  • Frequency and localization of relapses and/or metastases
  • Change in hemoglobin from baseline during therapy
  • Quality of life as assessed by the Functional Assessment of Cancer Therapy-Anemia
  • Type, frequency, and degree of adverse events
  • Safety
  • Vital signs
  • Number of treatment failures within 6 months after beginning RCT (stage II)

Estimated Enrollment: 450
Study Start Date: July 2002
Detailed Description:

OBJECTIVES:

  • Compare the effectiveness of epoetin beta vs standard care for anemia management, in terms of increased hemoglobin levels and the correlation with reduced relapse/treatment failure rate, in patients with stage IIB, III, or IVA cervical cancer treated with cisplatin and radiotherapy.
  • Compare the safety of these regimens in these patients.
  • Compare the relapse-free and overall survival of patients treated with these regimens.
  • Compare the frequency and localization of relapses and metastases in patients treated with these regimens.
  • Compare the quality of life of patients treated with these regimens.
  • Compare the type, frequency, and degree of adverse events in patients treated with these regimens.
  • Compare the overall response rate in patients treated with these regimens.

OUTLINE: This is a randomized, open-label, parallel-group, multicenter study. Patients are stratified according to country, disease stage, and brachytherapy technique. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo radiotherapy 5 days a week for 6 weeks. Patients also undergo high-dose rate, low-dose rate, or boost brachytherapy. Patients receive cisplatin IV beginning on day 1 of radiotherapy and continuing weekly for 6 weeks. Patients also receive epoetin beta subcutaneously 3 times a week beginning 2 weeks before radiotherapy and continuing for 8 weeks.
  • Arm II: Patients undergo radiotherapy and brachytherapy and receive cisplatin as in arm I.

Quality of life is assessed at baseline, after the last treatment, and at 3 months.

Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 80-450 patients will be accrued for this study within 4-22.5 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage IIB, III, or IVA cervical cancer

    • No chorion carcinoma or neuroendocrine small cell carcinoma
    • Previously untreated disease
  • Must be scheduled to undergo radiotherapy and receive cisplatin as primary therapy
  • Hemoglobin 8.0-13.0 g/dL
  • No relevant acute bleeding within the past 3 months, including anemia caused by gross bleeding from tumor
  • No distant metastasis
  • No positive para-aortic lymph nodes

PATIENT CHARACTERISTICS:

Age

  • Over 18

Performance status

  • WHO 0-2

Life expectancy

  • At least 3 months

Hematopoietic

  • See Disease Characteristics
  • WBC greater than 3,000/mm3
  • Platelet count greater than 100,000/mm3
  • No hemolytic anemia
  • No transferrin saturation less than 20% that cannot be treated with IV iron
  • No hemoglobinopathies (i.e., sickle cell disease or thalassemia of all types)

Hepatic

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • Transaminases no greater than 2.5 times ULN
  • Alkaline phosphatase no greater than 2.5 times ULN

Renal

  • Creatinine clearance greater than 60 mL/min

Cardiovascular

  • No chronic heart failure
  • No New York Heart Association class II-IV heart disease
  • No uncontrolled arterial hypertension (systolic blood pressure at least 170 mmHg, diastolic blood pressure at least 100 mmHg)
  • No prior deep vein thrombosis
  • No thrombocytosis

Other

  • No vitamin B12 deficiency
  • No folic acid deficiency
  • No newly diagnosed (unstable) epilepsy
  • No acute infection
  • No other malignancy within the past 5 years except basal cell carcinoma in situ
  • No known peripheral neuropathy or moto-sensory neurotoxicity grade 2 or greater
  • No impaired hearing grade 2 or greater
  • No hypersensitivity to benzyl alcohol, benzoic acid, benzalkonium chloride, or any excipients of cisplatin preparations
  • Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • At least 3 months since prior epoetins or related compounds

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • See Disease Characteristics
  • No prior radiotherapy for cervical cancer

Surgery

  • Not specified

Other

  • At least 30 days since prior investigational drugs
  • No prior systemic antineoplastic therapy for cervical cancer
  • No other concurrent investigational drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00046969

Locations
Germany
Martin Luther Universitaet
Halle, Germany, D-06097
Sponsors and Collaborators
AGO Study Group
Investigators
Study Chair: Heinz Koelbl, MD Martin-Luther-Universität Halle-Wittenberg
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00046969     History of Changes
Other Study ID Numbers: CDR0000257189, AGOSG-OVAR-MO16375-MARCH, EU-20217, ROCHE-MO16375, ROCHE-RO2053859
Study First Received: October 3, 2002
Last Updated: May 9, 2009
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
anemia
stage IIB cervical cancer
stage III cervical cancer
stage IVA cervical cancer
 cervical adenosquamous cell carcinoma
cervical squamous cell carcinoma
cervical adenocarcinoma

Additional relevant MeSH terms:
Anemia
Uterine Cervical Neoplasms
Hematologic Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
 Uterine Diseases
Genital Diseases, Female
Cisplatin
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013